Birker, Sebastian
Meier, Juris J.
Nauck, Michael A.
Funding for this research was provided by:
Universitätsklinikum der Ruhr-Universität Bochum
Article History
Received: 29 December 2021
Accepted: 28 November 2022
First Online: 6 December 2022
Competing interests
: MAN has been member on advisory boards or has consulted with Boehringer Ingelheim, Eli Lilly & Co., Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. He has received grant support from AstraZeneca, Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and NovoNordisk, outside the submitted work. He has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. JJM reports personal fees from Astra Zeneca, Eli Lilly, and Servier; grants and personal fees from Boehringer Ingelheim, MSD, Novo Nordisk, and Sanofi, outside the submitted work. SB has nothing to declare.